<DOC>
	<DOC>NCT00847834</DOC>
	<brief_summary>To analyse the control rate of irbesartan/hydrochlorothiazide(HCTZ) (COAPROVEL) in the treatment of patients with mild to moderate primary hypertension.</brief_summary>
	<brief_title>Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Inclusion criteria: Systolic blood pressure &lt; 180 mmHg 90 mmHg ≤ Diastolic blood pressure &lt; 110 mmHg Exclusion criteria: Pregnancy or lactation. Women of child bearing potential (not postmenopausal) should be using a reliable contraceptive method Known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular stenosis, etc.) Presence of clinically significant ventricular or supraventricular arrhythmias, or second or third degree atrioventricular block, or sick sinus syndrome ALAT[SGPT]&gt;2 times of upper limit， ASAT[SGOT]&gt;2 times of upper limit Patients with known renal disease Serum potassium &gt; normal upper limit Uncontroled BD（FBG＞10mmol/L or PBG＞12.22mmol/L) Patients treated with tricyclic antidepressants Clinical hematological disease. Patients with a history of irbesartan, or hydrochlorothiazide sensitivity defined as irbesartan, or hydrochlorothiazide discontinuation due to medically significant adverse effects. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>